Profil bibliographique

Ronan Andrew McLaughlin

Informations fournies par OpenAlex. Research Africa ne déduit ni nationalité, ni poste, ni coordonnées personnelles.

35Publications signalées

109Citations signalées

3Affiliations récentes

Institutions déclarées

University Health Network University of Toronto Princess Margaret Cancer Centre

Domaines associés

Esophageal Cancer Research and TreatmentGastric Cancer Management and OutcomesPancreatic and Hepatic Oncology ResearchHealth Systems, Economic Evaluations, Quality of LifeEconomic and Financial Impacts of Cancer

Publications récentes

2026 conference-abstractOpenAlex

GATA6 expression with CA19-9 levels as biomarkers in resectable pancreatic adenocarcinoma treated with neoadjuvant modified FOLFIRINOX in the NeoPancONE trial.

Rich Ericson King, Ronan Andrew McLaughlin, Derek J. Jonker, Paul J. Karanicolas et autres

0 citationsJournal of Clinical Oncology

2026 conference-abstractOpenAlex

A real-world comparison of overall survival (OS) in deficient mismatch repair/microsatellite instability high (dMMR) versus proficient mismatch repair/microsatellite instability low (pMMR) disease in gastroesophageal (GE) cancer patients (pts).

François Jobin Gervais, Katherine Lajkosv, Yvonne Bach, Hiroko Aoyama et autres

0 citationsJournal of Clinical Oncology

2026 conference-abstractOpenAlex

Optimizing nutrition in patients with pancreatic cancer (NUANCE study).

Ronan Andrew McLaughlin, Shari Moura, Sarah M. Buchanan, Lorena Lazar et autres

0 citationsJournal of Clinical Oncology

Accès ouvert 2026 conference-abstractOpenAlex

Genomic characterization of resectable pancreatic ductal adenocarcinoma (r-PDAC) on the NeoPancONE trial.

Ronan Andrew McLaughlin, Amy Xin Wei Zhang, Michelle Chan‐Seng‐Yue, Sabiq Chaudhary et autres

0 citationsJournal of Clinical Oncology

Accès ouvert 2026 conference-abstractOpenAlex

Impact of smoking on immunotherapy outcomes in gastric, gastro-esophageal junction, and esophageal cancers (G/GEJ/EC): A real-world analysis.

Nadia Ghazali, Hiroko Aoyama, Yvonne Bach, Katherine Lajkosz et autres

0 citationsJournal of Clinical Oncology

Accès ouvert 2025 articleOpenAlex

Operational determinants of recruitment and biospecimen collection in translational observational studies: a multi-site comparative analysis

Ciarán Devoy, Ronan Andrew McLaughlin, Christopher Cronin, Rachel Clarke et autres

0 citationsJournal of Translational Medicine

2025 erratumOpenAlex

Erratum: PASS-01: Randomized Phase II Trial of Modified FOLFIRINOX Versus Gemcitabine/Nab-Paclitaxel and Molecular Correlatives for Previously Untreated Metastatic Pancreatic Cancer

Jennifer J. Knox, Grainne M. O’Kane, Daniel A. King, Daniel A. Laheru et autres

3 citationsJournal of Clinical Oncology

Accès ouvert 2025 articleOpenAlex

PASS-01: Randomized Phase II Trial of Modified FOLFIRINOX Versus Gemcitabine/Nab-Paclitaxel and Molecular Correlatives for Previously Untreated Metastatic Pancreatic Cancer

Jennifer J. Knox, Grainne M. O’Kane, Daniel A. King, Daniel A. Laheru et autres

37 citationsJournal of Clinical Oncology

Accès ouvert 2025 articleOpenAlex

Neoadjuvant chemoradiation in older Irish adult patients with oesophageal cancer: a retrospective institutional review of clinical outcomes and hematological toxicity

Ronan Andrew McLaughlin, David McMahon, Christopher Cluxton, O.M. Fitzpatrick et autres

0 citationsBMC Cancer

Accès ouvert 2025 preprintOpenAlex

Operational Determinants of Recruitment and Biospecimen Collection in Translational Observational Studies: A Multi-Site Comparative Analysis

Ciarán Devoy, Ronan Andrew McLaughlin, Christopher Cronin, Rachel Clarke et autres

0 citationsResearch Square

Accès ouvert 2025 conference-abstractOpenAlex

8-year outcomes of enzalutamide (ENZA) versus a non-steroidal anti-androgen (NSAA) for metastatic, hormone-sensitive prostate cancer (ENZAMET; ANZUP 1304).

Alison Yan Zhang, Ian D. Davis, Hayley Thomas, Ronan Andrew McLaughlin et autres

9 citationsJournal of Clinical Oncology

Accès ouvert 2025 conference-abstractOpenAlex

Adaptive organoid-based precision therapy study in pancreatic cancer (ADOPT): A phase II single-arm study to evaluate the efficacy of patient-derived organoid (PDO)-directed therapy in advanced pancreatic ductal adenocarcinoma (PDAC).

Ronan Andrew McLaughlin, Nikta Feizi, Felix E.G. Beaudry, Eugenia Flores‐Figueroa et autres

0 citationsJournal of Clinical Oncology

Notice OpenAlex

BNTIC News n’est pas le producteur de ces données. Recherche à la demande dans Crossref et Europe PMC, sans clé ; OpenAlex reste optionnel. Aucun service payant requis, aucune réponse conservée. Sources et limites.